{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:26Z","timestamp":1791245186290,"version":"4.1.0"},"reference-count":126,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite advances in cancer treatments with significant improvement in patient outcomes, chemotherapy, targeted molecular therapies and radiotherapy may cause a range of cardiovascular complications, such as cancer therapy-related cardiac dysfunction (CTRCD), which represents a broad spectrum of possible presentation and aetiological link with the broad scope of various cancer therapies, including chemotherapy, targeted agents, immunotherapies, and radiation therapy, aiming at reducing the associated morbidity and mortality. However, practical guidelines on the primary prevention of CTRCD in high-risk patients, a key element in improving prognosis, are lacking in cancer patients and related evidence remains inconclusive. This Clinical Consensus Statement, authored by experts from the Heart Failure Association (HFA) and the European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC), and the ESC Council of Cardio-Oncology, aims to discuss the definition and epidemiology of CTRCD, the implicated factors for risk stratification, and the appropriate early diagnostic pathways, while focusing on lifestyle modifications, and pharmacological interventions to reduce the incidence of CTRCD. In addition, a holistic cardio-oncology management approach is advised for prevention and long-term management.<\/jats:p>","DOI":"10.1002\/ejhf.3753","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T16:50:23Z","timestamp":1752857423000},"page":"2084-2099","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prevention of Cancer Therapy-Related Cardiac Dysfunction and Heart Failure in Cancer Patients and Survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology"],"prefix":"10.1093","volume":"27","author":[{"given":"Amina","family":"Rakisheva","sequence":"first","affiliation":[{"name":"City Cardiology Center , Almaty ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"Heart Failure and Cardio-Oncology Unit, Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Attanasio","sequence":"additional","affiliation":[{"name":"Cardiology University Department, IRCCS Policlinico San Donato , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni Bayes","family":"Genis","sequence":"additional","affiliation":[{"name":"Heart Institute, Hospital Universitari Germans Trias i Poujol , Badalona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"Universite Paris Cite, INSEM U942, Cardiology Department, Lariboisiere Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Gulati","sequence":"additional","affiliation":[{"name":"Division of Medicine, Department of Cardiology, Oslo University Hospital , Oslo ,","place":["Norway"]},{"name":"K.G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Halle","sequence":"additional","affiliation":[{"name":"Department of Preventive Sports Medicine and Sports Cardiology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreena","family":"Hill","sequence":"additional","affiliation":[{"name":"School of Nursing and Paramedic Science, Ulster University , Londonderry ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Lopez","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute , Madrid ,","place":["Spain"]},{"name":"Cardiology Department, Hospital Universitario Quironsalud , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Centre of Excellence, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Moura","sequence":"additional","affiliation":[{"name":"Armed Forces Hospital , Porto ,","place":["Portugal"]},{"name":"Faculty of Medicine of University of Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Science, Federico II University , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"van Linthout","sequence":"additional","affiliation":[{"name":"BIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health (BIH) at Charit\u00e9 - Universit\u00e4tmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Vassiliou","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia and Norfolk and Norwich University Hospital , Norwich ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Ziya","family":"Sener","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcentrum, Erasmus MC , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhabbat","family":"Bekbosynova","sequence":"additional","affiliation":[{"name":"UMC , Astana ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome , Rome ,","place":["Italy"]},{"name":"IRCCS San Raffaele , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Piepoli","sequence":"additional","affiliation":[{"name":"Cardiology University Department, IRCCS Policlinico San Donato , Milan ,","place":["Italy"]},{"name":"Department of Biomedical Sciences for Health, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2026080802432800400_ejhf3753-bib-0001","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080802432800400_ejhf3753-bib-0002","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080802432800400_ejhf3753-bib-0003","doi-asserted-by":"crossref","DOI":"10.1002\/clc.24269","article-title":"Incidence of chemotherapy-related cardiac dysfunction in cancer patients","volume":"47","author":"Deng","year":"2024","journal-title":"Clin Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080802432800400_ejhf3753-bib-0005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0006","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0007","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular complications of cancer therapy: Best practices in diagnosis, prevention, and management: Part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0008","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Cancer diagnosis in patients with heart failure: Epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0009","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14228","article-title":"Mtor inhibitors associated with higher cardiovascular adverse events \u2013 a large population database analysis","volume":"35","author":"Nguyen","year":"2021","journal-title":"Clin Transplant"},{"key":"2026080802432800400_ejhf3753-bib-0010","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14051754","article-title":"Real-world data on osimertinib-associated cardiac toxicity","volume":"14","author":"Agbarya","year":"2025","journal-title":"J Clin Med"},{"key":"2026080802432800400_ejhf3753-bib-0011","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1002\/cam4.3938","article-title":"Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries","volume":"10","author":"Guha","year":"2021","journal-title":"Cancer Med"},{"key":"2026080802432800400_ejhf3753-bib-0012","article-title":"Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States","volume":"6","author":"Jain","year":"2021","journal-title":"ESMO Open"},{"key":"2026080802432800400_ejhf3753-bib-0013","first-page":"52","article-title":"Cardiac adverse events after chimeric antigen receptor (CAR) T cell therapies: An updated systematic review and meta-analysis","volume":"10","author":"Maleki","year":"2024","journal-title":"Cardiooncology"},{"key":"2026080802432800400_ejhf3753-bib-0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation-induced cardiovascular disease: Review of an underrecognized pathology","volume":"10","author":"Belzile-Dugas","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026080802432800400_ejhf3753-bib-0015","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: The CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080802432800400_ejhf3753-bib-0016","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2026080802432800400_ejhf3753-bib-0017","first-page":"21","article-title":"The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment","volume":"8","author":"Andres","year":"2022","journal-title":"Cardiooncology"},{"key":"2026080802432800400_ejhf3753-bib-0018","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jcmg.2022.06.014","article-title":"Global circumferential and radial strain among patients with immune checkpoint inhibitor myocarditis","volume":"15","author":"Quinaglia","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080802432800400_ejhf3753-bib-0019","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0020","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ejhf.1172","article-title":"Anthracycline-induced cardiomyopathy: Secrets and lies","volume":"20","author":"Farmakis","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0021","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/eurheartj\/ehae188","article-title":"Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1\u03b1","volume":"45","author":"Zhou","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080802432800400_ejhf3753-bib-0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013754","article-title":"Reverse cardio-oncology: Cancer development in patients with cardiovascular disease","volume":"9","author":"Aboumsallem","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026080802432800400_ejhf3753-bib-0023","article-title":"Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment: A meta-analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0024","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.736854","article-title":"Risk factors for anthracycline-induced cardiotoxicity","volume":"8","author":"Qiu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026080802432800400_ejhf3753-bib-0025","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/cvr\/cvaa222","article-title":"Cardiac dysfunction in cancer patients: Beyond direct cardiomyocyte damage of anticancer drugs: Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart","volume":"116","author":"Tocchetti","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2026080802432800400_ejhf3753-bib-0026","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","article-title":"Cardiovascular toxicity induced by kinase inhibitors: Mechanisms and preclinical approaches","volume":"33","author":"Lamore","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"2026080802432800400_ejhf3753-bib-0027","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0028","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1172\/JCI44583","article-title":"Impaired thymic tolerance to \u03b1-myosin directs autoimmunity to the heart in mice and humans","volume":"121","author":"Lv","year":"2011","journal-title":"J Clin Investig"},{"key":"2026080802432800400_ejhf3753-bib-0029","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"},{"key":"2026080802432800400_ejhf3753-bib-0030","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"Euw","year":"2009","journal-title":"J Transl Med"},{"key":"2026080802432800400_ejhf3753-bib-0031","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026080802432800400_ejhf3753-bib-0032","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0033","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"2026080802432800400_ejhf3753-bib-0034","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/eurheartj\/ehad175","article-title":"CAR T-cell cancer therapies: Do not forget the heart","volume":"44","author":"Totzeck","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080802432800400_ejhf3753-bib-0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.recesp.2016.12.021","article-title":"Cardio-onco-hematology in clinical practice. Position paper and recommendations","volume":"70","author":"L\u00f3pez-Fern\u00e1ndez","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026080802432800400_ejhf3753-bib-0036","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: Atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0037","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer treatment-induced arrhythmias: Focus on chemotherapy and targeted therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026080802432800400_ejhf3753-bib-0038","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"50","author":"Kirchhof","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026080802432800400_ejhf3753-bib-0039","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study","volume":"10","author":"Forni","year":"1992","journal-title":"J Clin Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0040","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: An underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0041","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jcmg.2018.04.028","article-title":"Radiation-associated cardiac disease","volume":"11","author":"Desai","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080802432800400_ejhf3753-bib-0042","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/cpt.614","article-title":"Cardio-oncology: Progress in diagnosis and treatment of cardiac dysfunction","volume":"101","author":"Tromp","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026080802432800400_ejhf3753-bib-0043","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.2016.69.8480","article-title":"Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures","volume":"35","author":"Bogaard","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0044","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"key":"2026080802432800400_ejhf3753-bib-0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jacc.2014.11.035","article-title":"Abnormal exercise response in long-term survivors of Hodgkin lymphoma treated with thoracic irradiation","volume":"65","author":"Groarke","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0046","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2018.04.005","article-title":"The role of the clinical examination in patients with heart failure","volume":"6","author":"Thibodeau","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0047","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: A position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0048","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jcmg.2020.10.024","article-title":"Fast strain-encoded cardiac magnetic resonance for diagnostic classification and risk stratification of heart failure patients","volume":"14","author":"Korosoglou","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080802432800400_ejhf3753-bib-0049","first-page":"977","article-title":"Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50\u201359% treated with anthracyclines","volume":"16","author":"Mousavi","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080802432800400_ejhf3753-bib-0050","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/ejhf.3412","article-title":"The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Keramida","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0051","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular imaging in contemporary cardio-oncology: A scientific statement from the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"key":"2026080802432800400_ejhf3753-bib-0052","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0053","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaccao.2022.12.007","article-title":"Screening for coronary artery disease in cancer survivors: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Velusamy","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026080802432800400_ejhf3753-bib-0054","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1093\/eurheartj\/ehae637","article-title":"Breast cancer and cardiovascular health","volume":"45","author":"L\u00f3pez-Fern\u00e1ndez","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080802432800400_ejhf3753-bib-0055","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00392-022-02001-6","article-title":"Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients \u2013 a large monocenter cohort study","volume":"112","author":"Finke","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0056","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245885","article-title":"Developing cardio-oncology programs in the new era: Beyond ventricular dysfunction due to cancer treatments","volume":"15","author":"Pons-Riverola","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026080802432800400_ejhf3753-bib-0057","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11897-024-00662-0","article-title":"Relevance of cardiovascular exercise in cancer and cancer therapy-related cardiac dysfunction","volume":"21","author":"Wernhart","year":"2024","journal-title":"Curr Heart Fail Rep"},{"key":"2026080802432800400_ejhf3753-bib-0058","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/ijc.34846","article-title":"Healthy lifestyle and cancer survival: A multinational cohort study","volume":"154","author":"Bian","year":"2024","journal-title":"Int J Cancer"},{"key":"2026080802432800400_ejhf3753-bib-0059","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0060","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: A scientific statement from the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"2026080802432800400_ejhf3753-bib-0061","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(22)00242-2","article-title":"Management of common clinical problems experienced by survivors of cancer","volume":"399","author":"Emery","year":"2022","journal-title":"Lancet"},{"key":"2026080802432800400_ejhf3753-bib-0062","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"key":"2026080802432800400_ejhf3753-bib-0063","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: Where these entities intersect: A scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"2026080802432800400_ejhf3753-bib-0064","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","article-title":"Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: A systematic review and meta-analysis","volume":"34","author":"Guenancia","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0065","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41574-024-01032-5","article-title":"The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies","volume":"20","author":"Lysaght","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026080802432800400_ejhf3753-bib-0066","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1161\/CIR.0000000000001122","article-title":"Supervised exercise training for chronic heart failure with preserved ejection fraction: A scientific statement from the American Heart Association and American College of Cardiology","volume":"147","author":"Sachdev","year":"2023","journal-title":"Circulation"},{"key":"2026080802432800400_ejhf3753-bib-0067","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.recesp.2020.11.014","article-title":"Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC","volume":"74","author":"Mart\u00edn Garc\u00eda","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026080802432800400_ejhf3753-bib-0068","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080802432800400_ejhf3753-bib-0069","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jacc.2022.07.004","article-title":"Exercise for primary and secondary prevention of cardiovascular disease: JACC Focus Seminar 1\/4","volume":"80","author":"Tucker","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41569-018-0065-1","article-title":"Exercise benefits in cardiovascular disease: Beyond attenuation of traditional risk factors","volume":"15","author":"Fiuza-Luces","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0071","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1200\/JCO.23.00058","article-title":"Pan-cancer analysis of postdiagnosis exercise and mortality","volume":"41","author":"Lavery","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104272","article-title":"Feasibility metrics of exercise interventions during chemotherapy: A systematic review","volume":"195","author":"Kearney","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026080802432800400_ejhf3753-bib-0073","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcad.2022.10.005","article-title":"Determinants of oxygen utilization in breast cancer: Similarities between heart failure with preserved ejection fraction","volume":"74","author":"Haykowsky","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"2026080802432800400_ejhf3753-bib-0074","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2011.39.9014","article-title":"Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum","volume":"30","author":"Jones","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0075","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad007","article-title":"Prospective associations between accelerometry-derived physical activity and sedentary behaviors and mortality among cancer survivors","volume":"7","author":"Salerno","year":"2023","journal-title":"JNCI Cancer Spectr"},{"key":"2026080802432800400_ejhf3753-bib-0076","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1249\/MSS.0000000000003452","article-title":"Resistance exercise and skeletal muscle\u2013related outcomes in patients with cancer: A systematic review","volume":"56","author":"Kang","year":"2024","journal-title":"Med Sci Sports Exerc"},{"key":"2026080802432800400_ejhf3753-bib-0077","first-page":"230","article-title":"American Cancer Society nutrition and physical activity guideline for cancer survivors","volume":"72","author":"Rock","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2026080802432800400_ejhf3753-bib-0078","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1200\/JCO.22.00687","article-title":"Exercise, diet, and weight management during cancer treatment: ASCO guideline","volume":"40","author":"Ligibel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0079","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/eurjpc\/zwab007","article-title":"Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: Why and how: A position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology","volume":"29","author":"Hansen","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0080","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1177\/2047487319832975","article-title":"Cardiovascular effects of electronic cigarettes: A systematic review and meta-analysis","volume":"26","author":"Skotsimara","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0081","first-page":"1388","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"379","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080802432800400_ejhf3753-bib-0082","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000510","article-title":"Dietary fats and cardiovascular disease: A Presidential Advisory from the American Heart Association","volume":"136","author":"Sacks","year":"2017","journal-title":"Circulation"},{"key":"2026080802432800400_ejhf3753-bib-0083","article-title":"Dietary interventions for adult cancer survivors","volume":"2019","author":"Burden","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080802432800400_ejhf3753-bib-0084","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080802432800400_ejhf3753-bib-0085","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurjpc\/zwac006","article-title":"Mental health-related risk factors and interventions in patients with heart failure: A position paper endorsed by the European Association of Preventive Cardiology (EAPC)","volume":"29","author":"Ladwig","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0086","article-title":"Psychological interventions for depression and anxiety in patients with coronary heart disease, heart failure or atrial fibrillation","volume":"4","author":"Ski","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080802432800400_ejhf3753-bib-0087","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0088","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0089","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 \u00d7\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080802432800400_ejhf3753-bib-0090","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): A randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0091","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: A randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0092","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","article-title":"Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial","volume":"148","author":"Henriksen","year":"2023","journal-title":"Circulation"},{"key":"2026080802432800400_ejhf3753-bib-0093","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jaccao.2024.07.010","article-title":"Preventing cardiac damage in patients treated for breast cancer and lymphoma: The PROACT clinical trial","volume":"6","author":"Austin","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026080802432800400_ejhf3753-bib-0094","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(23)00637-X","article-title":"Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): A randomised, controlled, phase 2b trial","volume":"25","author":"Armenian","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026080802432800400_ejhf3753-bib-0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010312","article-title":"Neprilysin inhibition in the prevention of anthracycline-induced cardiotoxicity","volume":"15","author":"Sobiborowicz-Sadowska","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026080802432800400_ejhf3753-bib-0096","first-page":"35","article-title":"Sacubitril\/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: Real-world data","volume":"7","author":"Frey","year":"2021","journal-title":"Cardiooncology"},{"key":"2026080802432800400_ejhf3753-bib-0097","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril-valsartan in cancer patients with heart failure","volume":"7","author":"Mart\u00edn-Garcia","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0098","first-page":"24","article-title":"Use of sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy","volume":"6","author":"Gregorietti","year":"2020","journal-title":"Cardiooncology"},{"key":"2026080802432800400_ejhf3753-bib-0099","first-page":"33","article-title":"Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: A randomized, placebo-controlled, multicenter trial","volume":"7","author":"Mecinaj","year":"2021","journal-title":"Cardiooncology"},{"key":"2026080802432800400_ejhf3753-bib-0100","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/ehf2.14466","article-title":"Sacubitril\/valsartan for cardioprotection in breast cancer (MAINSTREAM): Design and rationale of the randomized trial","volume":"10","author":"Tajstra","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0101","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0102","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026080802432800400_ejhf3753-bib-0103","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer","volume":"109","author":"Chiang","year":"2023","journal-title":"Heart"},{"key":"2026080802432800400_ejhf3753-bib-0104","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026080802432800400_ejhf3753-bib-0105","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: A systematic review and meta-analysis","author":"Bhalraam","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026080802432800400_ejhf3753-bib-0106","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jaccao.2024.02.004","article-title":"Dexrazoxane to prevent cardiotoxicity in adults treated with anthracyclines: JACC: CardioOncology controversies in cardio-oncology","volume":"6","author":"Upshaw","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026080802432800400_ejhf3753-bib-0107","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","article-title":"Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: A Bayesian network meta-analysis","volume":"51","author":"Yamaguchi","year":"2015","journal-title":"Eur J Cancer"},{"key":"2026080802432800400_ejhf3753-bib-0108","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/ejhf.3445","article-title":"Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction \u2013 the ESC EORP Heart Failure III Registry","volume":"26","author":"Lund","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0109","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCULATIONAHA.122.062814","article-title":"Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: The BREXIT study","volume":"147","author":"Foulkes","year":"2023","journal-title":"Circulation"},{"key":"2026080802432800400_ejhf3753-bib-0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/1047-2797(93)90070-K","article-title":"The health risks of smoking the framingham study: 34\u2009years of follow-up","volume":"3","author":"Freund","year":"1993","journal-title":"Ann Epidemiol"},{"key":"2026080802432800400_ejhf3753-bib-0111","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11764-020-00949-w","article-title":"Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trial","volume":"15","author":"Chow","year":"2021","journal-title":"J Cancer Surviv"},{"key":"2026080802432800400_ejhf3753-bib-0112","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0113","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3109\/15376516.2012.678406","article-title":"Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats","volume":"22","author":"Kim","year":"2012","journal-title":"Toxicol Mech Methods"},{"key":"2026080802432800400_ejhf3753-bib-0114","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res"},{"key":"2026080802432800400_ejhf3753-bib-0115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13105-013-0240-0","article-title":"Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice","volume":"69","author":"Ramanjaneyulu","year":"2013","journal-title":"J Physiol Biochem"},{"key":"2026080802432800400_ejhf3753-bib-0116","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: The STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"2026080802432800400_ejhf3753-bib-0117","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"key":"2026080802432800400_ejhf3753-bib-0118","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026080802432800400_ejhf3753-bib-0119","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ejhf.670","article-title":"Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: Results of a prospective cardiovascular long-term study","volume":"18","author":"Anker","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0120","article-title":"Ivabradine for the prevention of anthracycline-induced cardiotoxicity in female patients with primarily breast cancer: A prospective, randomized, open-label clinical trial","volume":"59","author":"\u010ciburien\u0117","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2026080802432800400_ejhf3753-bib-0121","article-title":"Immune checkpoint inhibitors-related myocarditis: A review of reported clinical cases","volume":"13","author":"Zotova","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2026080802432800400_ejhf3753-bib-0122","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"20","author":"Chou","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2026080802432800400_ejhf3753-bib-0123","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40119-023-00305-w","article-title":"Risk and management of patients with cancer and heart disease","volume":"12","author":"Hill","year":"2023","journal-title":"Cardiol Ther"},{"key":"2026080802432800400_ejhf3753-bib-0124","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ejhf.3102","article-title":"European Society of Cardiology Core Curriculum for cardio-oncology","volume":"26","author":"L\u00f3pez-Fern\u00e1ndez","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0125","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/ejhf.1336","article-title":"How to build a cardio-oncology service?","volume":"20","author":"Farmakis","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080802432800400_ejhf3753-bib-0126","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: Rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2084\/66833555\/eurjhf_27_11_2084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2084\/66833555\/eurjhf_27_11_2084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T06:43:51Z","timestamp":1786171431000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/11\/2084\/8470394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":126,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,18]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3753","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"2025-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}